Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

NEXT STORY
AIT Therapeutics Announces Oral and Poster Presentations at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland
PREV STORY
BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medivir announces that Janssen decided to start a phase IIb study of combinations of Simeprevir, Odalasvir and AL-335 for the treatment of hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Research & ...

author_avatar
NASDAQ Market News

Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients

author_avatar
NASDAQ Market News

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

author_avatar
NASDAQ Market News